Cargando...
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis—in spite of new treatments, approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Seq...
Gardado en:
| Publicado en: | Gastroenterology |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5010785/ https://ncbi.nlm.nih.gov/pubmed/26385075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2015.08.056 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|